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Abstract
Introduction Decitabine has been approved for the treatment of
myelodysplastic syndromes (MDS) in the United States and acute myeloid
leukemia (AML) in older patients in Europe. The definitions of MDS and AML
differ between the FAB and WHO classification, mainly with regards to
patients with 20 to 30% blasts in blood or bone marrow having MDS
according to the FAB classification (i.e. refractory anemia with excess blasts
[RAEB] or RAEB in transformation), but AML according to the WHO. In the
phase III trial 06011, we compared low-dose decitabine with best supportive
care (BSC) in patients ≥60 years with MDS according to the FAB classification
(Lübbert et al., J Clin Oncol. 2011;29:1987-96). Here, we examine trial 06011
for the efficacy and safety of decitabine in patients with AML according to
WHO and low proliferation, i.e., blast counts of 20 to 30%.
Patients and Methods Patients were randomly assigned to receive decitabine
or BSC. Decitabine 15 mg/m  was given intravenously over 4 hours every 8
hours for 3 consecutive days in 6-week cycles, with a maximum of 8 cycles.
Results were evaluated every 2nd cycle. In case of complete remission (CR) at
least 2 further courses were administered. Primary endpoint was overall
survival (OS). Response rates (CR; PR, partial remission; HI, hematologic
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improvement; PD, progressive disease), progression-free survival (PFS; time
from random assignment to PD, relapse or death), AML-free survival (AMLFS;
time from random assignment to AML according to FAB [>30% bone marrow
blasts] or death), and toxicity were secondary endpoints.
Results Applying the WHO criteria to the 233 patients enrolled onto the trial,
164 had MDS and 50 had AML with blast counts of 20 to 30%. The remaining
19 patients were excluded from the present analyses. They comprised 14
patients with chronic myelomonocytic leukemia, 2 with AML and ≥40% blasts,
and 3 with no blast counts available.
Among the AML patients, 27 were in the decitabine and 23 in the BSC arm. In
both arms, the median age was 70 years. Of the patients in the decitabine
arm, 59% received 3 or more treatment cycles. Response rates in the
decitabine and the BSC arm were as follows: CR, 11% vs 0%; PR, 11% vs 0%;
HI, 11% vs 0%; and PD, 37% vs 74%. Compared with the patients receiving
BSC, those receiving decitabine had longer PFS (P=0.008; Table 1). However,
this did not translate into a significantly improved AMLFS or OS of the
decitabine treated patients, although median OS was 9.8 months, compared
to 5.9 months among patients receiving BSC only (Table 1). With regard to
toxicity differences between the decitabine and BSC arms, grade 1-2 nausea
was observed in 46% vs 14% and grade 3-4 febrile neutropenia in 19% vs 0%.
Among the MDS patients, those receiving decitabine (n=78) had a longer PFS
(P=0.07) but similar AMLFS and OS compared to the patients receiving BSC
only (n=86; Table 1). The impact of decitabine on PFS, AMLFS and OS did not
significantly differ between the AML and MDS patients (Table 1). Response
rates among the MDS patients in the decitabine and BSC arms were as
follows: CR, 14% vs 0%; PR, 4% vs 0%; HI, 18% vs 2%; and PD, 23% vs 66%.
Conclusions Our data point to the clinically relevant efficacy of decitabine
given in the 3-day schedule among patients with AML and low blast counts,
particularly by delaying progression or relapse. No impact of decitabine,
compared to BSC or low-dose cytarabine, on OS in older patients with AML
and 20 to 30% marrow blasts (median, 8.0 vs 6.1 months) has been
previously also reported by Kantarjian et al. (J Clin Oncol. 2012;30:2670-7).
In that study, decitabine was given with 20 mg/m /day on 5 days every 4
weeks; PFS was not presented. The prolonged PFS that we observe may be
used for example as non-intensive bridge to allogeneic stem cell
transplantation after reduced-toxicity conditioning. Due to the post-hoc
nature of our analyses and the relatively small patient numbers, further
studies appear warranted to fully establish the benefit of decitabine in AML
patients with low blast counts.
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